Read This First Before You Buy Ventyx Biosciences Inc (NASDAQ: VTYX) Stock

Ventyx Biosciences Inc (NASDAQ:VTYX) shares, rose in value, with the stock price down by -1.15% to the previous day’s close as strong demand from buyers drove the stock to $5.18.

Actively observing the price movement in the last trading, the stock closed the session at $5.24. The value of beta (5-year monthly) was 0.36. Referring to stock’s 52-week performance, its high was $40.58, and the low was $1.87. On the whole, VTYX has fluctuated by -42.44% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of Ventyx Biosciences Inc currently standing at about $306.91 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 27, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.69, which is expected to increase to -$0.34 for fiscal year -$2.67 and then to about -$2.59 by fiscal year 2025. Data indicates that the EPS growth is expected to be 19.10% in 2025, while the next year’s EPS growth is forecast to be 3.00%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VTYX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VTYX currently trading nearly -30.86% and -0.18% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.13, while the 7-day volatility ratio is showing 7.96% which for the 30-day chart, stands at 11.43%. Furthermore, Ventyx Biosciences Inc (VTYX)’s beta value is 0.29, and its average true range (ATR) is 0.75.

A comparison of Ventyx Biosciences Inc (VTYX) with its peers suggests the former has fared considerably weaker in the market. VTYX showed an intraday change of -1.15% in last session, and over the past year, it shrunk by -84.54%%.

Data on historical trading for Ventyx Biosciences Inc (NASDAQ:VTYX) indicates that the trading volumes over the past 10 days have averaged 1.57 million and over the past 3 months, they’ve averaged 4.38 million. According to company’s latest data on outstanding shares, there are 59.24 million shares outstanding.

Nearly 20.51% of Ventyx Biosciences Inc’s shares belong to company insiders and institutional investors own 83.18% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.45 million shares as on Mar 15, 2024, resulting in a short ratio of 1. According to the data, the short interest in Ventyx Biosciences Inc (VTYX) stood at 13.41% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 5.59 million. The stock has risen by 109.72% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VTYX stock heading into the next quarter.